Adipose tissue as an endocrine organ: Implications of its distribution on free fatty acid metabolism

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Free fatty acids (FFAs) are the main circulating lipid fuel in the post-absorptive state. Elevated plasma FFA concentrations are associated with increased endogenous glucose production rates and insulin resistance in skeletal muscle, whereas long-term exposure of pancreatic β-cells to elevated FFA impairs insulin secretion, with a consequently increased risk of developing type 2 diabetes. A range of adverse changes occur in the vascular endothelium in response to elevation of plasma FFA concentrations that are similar to key early steps in atherogenesis. These include reduced endothelium-dependent vasodilatation and increased expression of adhesion molecules. We have found that the majority of systemic plasma FFAs originate from upper-body subcutaneous fat, with lesser contributions from leg fat and intra-abdominal adipocytes, even in persons with abdominal obesity. However, systemic FFA concentrations correlate positively with visceral fat, so that FFA release from visceral depots appears to serve as a marker of systemic insulin resistance. In addition, the secretion of a range of bioactive substances from intra-abdominal adipocytes (adipokines) is disturbed, with potentially deleterious consequences for metabolism and overall cardiometabolic risk. Interventions that reduce circulating FFA, either due to or independently of weight loss, are likely to improve insulin sensitivity, β-cell function, and cardiovascular risk. Weight loss in overweight or obese patients would have the additional benefit of reducing intra-abdominal adiposity and tending to correct the pathologically altered adipokine secretion associated with abdominal obesity.

Original languageEnglish (US)
JournalEuropean Heart Journal, Supplement
Volume8
Issue numberB
DOIs
StatePublished - May 2006

Fingerprint

Nonesterified Fatty Acids
Adipose Tissue
Insulin Resistance
Adipokines
Intra-Abdominal Fat
Abdominal Obesity
Adipocytes
Weight Loss
Subcutaneous Fat
Vascular Endothelium
Adiposity
Vasodilation
Type 2 Diabetes Mellitus
Endothelium
Leg
Atherosclerosis
Skeletal Muscle
Insulin
Lipids
Glucose

Keywords

  • Abdominal obesity
  • Cardiovascular risk
  • Dyslipidaemia
  • Free fatty acids
  • Insulin resistance
  • Lipolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{89f96523baa34fefbc822a7671b40910,
title = "Adipose tissue as an endocrine organ: Implications of its distribution on free fatty acid metabolism",
abstract = "Free fatty acids (FFAs) are the main circulating lipid fuel in the post-absorptive state. Elevated plasma FFA concentrations are associated with increased endogenous glucose production rates and insulin resistance in skeletal muscle, whereas long-term exposure of pancreatic β-cells to elevated FFA impairs insulin secretion, with a consequently increased risk of developing type 2 diabetes. A range of adverse changes occur in the vascular endothelium in response to elevation of plasma FFA concentrations that are similar to key early steps in atherogenesis. These include reduced endothelium-dependent vasodilatation and increased expression of adhesion molecules. We have found that the majority of systemic plasma FFAs originate from upper-body subcutaneous fat, with lesser contributions from leg fat and intra-abdominal adipocytes, even in persons with abdominal obesity. However, systemic FFA concentrations correlate positively with visceral fat, so that FFA release from visceral depots appears to serve as a marker of systemic insulin resistance. In addition, the secretion of a range of bioactive substances from intra-abdominal adipocytes (adipokines) is disturbed, with potentially deleterious consequences for metabolism and overall cardiometabolic risk. Interventions that reduce circulating FFA, either due to or independently of weight loss, are likely to improve insulin sensitivity, β-cell function, and cardiovascular risk. Weight loss in overweight or obese patients would have the additional benefit of reducing intra-abdominal adiposity and tending to correct the pathologically altered adipokine secretion associated with abdominal obesity.",
keywords = "Abdominal obesity, Cardiovascular risk, Dyslipidaemia, Free fatty acids, Insulin resistance, Lipolysis",
author = "Jensen, {Michael Dennis}",
year = "2006",
month = "5",
doi = "10.1093/eurheartj/sul003",
language = "English (US)",
volume = "8",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "B",

}

TY - JOUR

T1 - Adipose tissue as an endocrine organ

T2 - Implications of its distribution on free fatty acid metabolism

AU - Jensen, Michael Dennis

PY - 2006/5

Y1 - 2006/5

N2 - Free fatty acids (FFAs) are the main circulating lipid fuel in the post-absorptive state. Elevated plasma FFA concentrations are associated with increased endogenous glucose production rates and insulin resistance in skeletal muscle, whereas long-term exposure of pancreatic β-cells to elevated FFA impairs insulin secretion, with a consequently increased risk of developing type 2 diabetes. A range of adverse changes occur in the vascular endothelium in response to elevation of plasma FFA concentrations that are similar to key early steps in atherogenesis. These include reduced endothelium-dependent vasodilatation and increased expression of adhesion molecules. We have found that the majority of systemic plasma FFAs originate from upper-body subcutaneous fat, with lesser contributions from leg fat and intra-abdominal adipocytes, even in persons with abdominal obesity. However, systemic FFA concentrations correlate positively with visceral fat, so that FFA release from visceral depots appears to serve as a marker of systemic insulin resistance. In addition, the secretion of a range of bioactive substances from intra-abdominal adipocytes (adipokines) is disturbed, with potentially deleterious consequences for metabolism and overall cardiometabolic risk. Interventions that reduce circulating FFA, either due to or independently of weight loss, are likely to improve insulin sensitivity, β-cell function, and cardiovascular risk. Weight loss in overweight or obese patients would have the additional benefit of reducing intra-abdominal adiposity and tending to correct the pathologically altered adipokine secretion associated with abdominal obesity.

AB - Free fatty acids (FFAs) are the main circulating lipid fuel in the post-absorptive state. Elevated plasma FFA concentrations are associated with increased endogenous glucose production rates and insulin resistance in skeletal muscle, whereas long-term exposure of pancreatic β-cells to elevated FFA impairs insulin secretion, with a consequently increased risk of developing type 2 diabetes. A range of adverse changes occur in the vascular endothelium in response to elevation of plasma FFA concentrations that are similar to key early steps in atherogenesis. These include reduced endothelium-dependent vasodilatation and increased expression of adhesion molecules. We have found that the majority of systemic plasma FFAs originate from upper-body subcutaneous fat, with lesser contributions from leg fat and intra-abdominal adipocytes, even in persons with abdominal obesity. However, systemic FFA concentrations correlate positively with visceral fat, so that FFA release from visceral depots appears to serve as a marker of systemic insulin resistance. In addition, the secretion of a range of bioactive substances from intra-abdominal adipocytes (adipokines) is disturbed, with potentially deleterious consequences for metabolism and overall cardiometabolic risk. Interventions that reduce circulating FFA, either due to or independently of weight loss, are likely to improve insulin sensitivity, β-cell function, and cardiovascular risk. Weight loss in overweight or obese patients would have the additional benefit of reducing intra-abdominal adiposity and tending to correct the pathologically altered adipokine secretion associated with abdominal obesity.

KW - Abdominal obesity

KW - Cardiovascular risk

KW - Dyslipidaemia

KW - Free fatty acids

KW - Insulin resistance

KW - Lipolysis

UR - http://www.scopus.com/inward/record.url?scp=33749038908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749038908&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/sul003

DO - 10.1093/eurheartj/sul003

M3 - Article

AN - SCOPUS:33749038908

VL - 8

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - B

ER -